Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950773 | 0.84 | ADORA3 (0.49) | AHCYDOT1LPLA2G2A | |
| SCHEMBL22799204 | 0.74 | AHCY (0.55) | AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL23056493 | 0.74 | ENPP1 (0.46) | — | |
| SCHEMBL30744251 | 0.73 | ADORA3 (0.53) | AHCYHIF1ATMEM97SIGMAR1DOT1L | |
| SCHEMBL30861853 | 0.73 | HSP90B1 (0.55) | AHCYHIF1ATMEM97SIGMAR1 | |
| SCHEMBL29540124 | 0.72 | DOT1L (0.61) | AHCYDOT1LPRKACA | |
| SCHEMBL2697842 | 0.69 | P2RY1 (0.53) | — | |
| SCHEMBL4314015 | 0.68 | ADORA1 (0.61) | — | |
| SCHEMBL29365543 | 0.68 | P2RY1 (0.55) | — | |
| SCHEMBL25607786 | 0.68 | P2RY1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | AHCY 3672/4885HIF1A 4006/4885TMEM97 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.